Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Phase 1/2 Completed 45 enrolled Tanta University

Non-randomizedParallel-groupTriple-blindTreatment

Summary

In this prospective trial the investigators plan to study the efficacy of erythropoietin as a therapeutic agent in neonates who suffer from brain injury following perinatal asphyxia.

Timeline

Start: 2007-10
Primary completion: 2008-12
Completion: 2009-06

Publications

Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010 May;125(5):e1135-42. doi: 10.1542/peds.2009-2268. Epub 2010 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	2500 iu/kg	Subcutaneous

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Summary

Timeline

Publications

Drugs

Indications